LM-317 / Sino Biopharm - LARVOL DELTA

Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b (AACR 2024) - "The novel ADC LM-317 targeting NaPi2b showed robust antitumor activity in vitro, and in the OC and NSCLC cell line derived models and PDX models. LM-317 could potentially provide therapeutic benefit to treat NaPi2b-positive tumors including OC and NSCLC in the future.Reference: 1.S. Banerjee et al."

Preclinical • Endocrine Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • SLC34A2